Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
51
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Protara Therapeutics Inc market cap is $155.77M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Protara Therapeutics Inc 52 week high is $7.82 as of November 15, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Protara Therapeutics Inc 52 week low is $2.09 as of November 15, 2026.
Protara Therapeutics Inc stock price today is $2.53.
Protara Therapeutics Inc stock price yesterday was $2.44.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Protara Therapeutics Inc's P/E ratio is -1.83.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Protara Therapeutics Inc P/B ratio is 1.0758.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Protara Therapeutics Inc 50-day moving average is $2.89.
